Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Carcinoma, Renal Cell 27Prostatic Neoplasms 13Kidney Neoplasms 10Neoplasm Metastasis 6Breast Neoplasms 5Neoplasms 4Melanoma 3Endometrial Neoplasms 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urogenital Neoplasms 1Urethral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Sezary Syndrome 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

pembrolizumab 6sargramostim 5Psychiatric Rehabilitation 5Early Intervention, Educational 5Magnetic Resonance Spectroscopy 4Gemcitabine 4Cyclophosphamide 4palbociclib 3Trastuzumab 3Therapeutics 3Standard of Care 3Radiotherapy 3Oxaliplatin 3Methods 3Irinotecan 3Interferon-alpha 3Fluorouracil 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3Docetaxel 3Bortezomib 3temsirolimus 2motexafin gadolinium 2entinostat 2cemiplimab 2cediranib 2Specimen Handling 2Radiosurgery 2Practice Guidelines as Topic 2Paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Colonic Neoplasms × temsirolimus × Genitourinary × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01183663 2016-06-03

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

M.D. Anderson Cancer Center

Phase 1 Completed
180 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryOther hematologic neoplasmPlasma cell

Breast Neoplasms, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Melanoma, Multiple Myeloma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡